WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

A Literature Review on Cystic Fibrosis

Ratna Ramchandra Chavan*

PG Student Shree Santkrupa college of pharmacy, Ghogaon. Pharmaceutics Karad, Tal karad Dist satara Maharashtra, pin code -415111, India

A B S T R A C T

Cystic fibrosis (CF) may be a multi-system wellness that principally have an effect on the lungs and system. CF is caused by a mutation (change) in citron known as the pancreatic fibrosis Tran's membrane electrical phenomenon regulator (CFTR) citron. This citron helps to regulate salt and water within the cell and affects the assembly of secretion, sweat and biological process fluids. The respiratory, gastrointestinal, musculoskeletal, genitourinary, and reproductive systems are just a few of the many body parts that are impacted by cystic fibrosis. . Women with CF may experience problems conceiving and carrying a child due to the build-up of mucus in their cervix. Men with CF who are infertile can nevertheless have children of their own since sperm production continues. Surgical procedures in cystic fibrosis are: **Bowel surgery,** Feeding tube**, Double-lung transplant.**

Keywords: Cystic fibrosis, multi-system, citron, **Bowel surgery, feeding tube, Double-lung transplant.**

1. Introduction

Cystic fibrosis (CF) may multi-system wellness that principally have an effect on the lungs and system. It results from in an exceedingly explicit sequence. Fibrosis affects the cell that turn out secretion, sweat and juice. CF is chromosome-recessiveive wellness. Chromosome means that the CF sequence isn't on the chromosome. In different words, each males and females will get CF. If the CF point mutation is paired with traditional sequence, thetraditional can do all the work and also the CF point mutation are recessive. This person won't have CF however are a carrier.

A carrier may be a somebody with one CF point mutation and one traditional sequence. A carrier has not symptoms and no wellness. Once each folks square measure carrier and every offer the kid a CF point mutation, there's no works right. The kid can have CF.

1.1. Occurrence:

CF is one in every of the foremost common genetic science (heritable, hereditary) disorder in Caucasoid race. Within the U. S., CF happens in one among of every three, 200 live white births. CF is unusual in Asian and most native yank tribes. It's being seen additional typically in Hispanics. It happens equally in males and females. In U. S. regarding 800 to 900 person's square measure diagnosed with CF yearly. There square measure about 30,000 individuals with

CF within the U. S. these days. Cystic fibrosis (CF) was thought-about to be nonexistent in Indian landmass. Studies on migrant Indian population in U. S. and up estimate frequency of CF as 1: 10 to 1: 40. CF in Indian youngsters is typically diagnosed late and advanced stage. [1]



Fig: Autosomal Recessive Inheritance

Sign and Symptoms:

The kind and extent of CF From person to person, symptoms can differ. Many different medical conditions have signs and symptoms similar to CF. This might make CF difficult to detect or diagnose.

Common signs of CF

- Skin that tastes salty
- Indicates weight gain
- Unusual bowel motions
- Wheezing
- Increased pulmonary mucous secretion and cough
- Pneumonia
- Nasal growths (small flesh growths within the nose)
- Clubbing (expansion) of the fingers and toes
- Fertility problems

Causes of CF:

The pancreatic fibrosis trans membrane electrical phenomenon regulator (CFTR) citron, which is mutated (changed), is the source of CF. This citron has an impact on the formation of secretion, perspiration, and biological process fluids as well as helping to manage salt and water within the cell.

Even if you just have one copy, you will still have the disease even if you don't show any symptoms. It implies that there is a chance you'll pass it on to your children. To transfer on the disease to their child, each parent must contain the defective citron for cystic fibrosis, CF, pancreatic fibrosis, mucoviscidosis, fibrosis, monogenic condition, or monogenic disease. In any physiological circumstance, there is a one in four (25%) chance that each parent who carries the citron will pass it on to their offspring.

1.2. Complications in CF:

Nasal polyps, persistent chronic sinusitis with macro cycle issues, pneumothorax, hemoptysis, bronchiectasis, atelectasis, hypertrophic pulmonary osteoarthropathy, and allergic Broncho pulmonary aspergillosis are all possible side effects of cystic fibrosis (ABPA).

1.3 Tables.

Table 1 - Classification of Drugs:

Name	Dose	Dosage form	Mechanism of action	Side effects
Bronchodilators Albuterol	4 to 8 puff every 30 min. up to 4 hrs. Then, every 1 to 4 hrs. as Needed.	Inhalation	Open airways by relaxing the muscle around the airways	Heartburn, headache
7% Hypertonic saline	4ml twice a daily	Inhalation	Increasing the amount of sodium (salt) in the airways	Increased cough, sore throat, chest tightness
Mucolytic Durance Alfa	2.5mg inhaled daily	Inhalation	Reduces the mucus viscosity in lungs, promoting improved Clearance of secretions.	Body ach, chest pain, trouble breathing.
Antibiotics Tobramycin	300mg twice a daily	Solution, capsule	To treat initial or new growth of p. aerugenosa from an airway culture.	Bloody nose, discoloration of sputum
CFTR Modulators Elexacaftor/ tezacaftor/ invocator	100mg/ 50mg/ 75mg / plus invocator 150mg	Oral tablets	Improving production, intracellular processing and function of defective CFTR protein.	Dizziness, rash ,headache, stomach pain

1.4. Screening & Testing:

A minimum of one organ system must have clinical symptoms that are consistent with CF, and there must be evidence of CFTR malfunction, often demonstrated by an abnormal sweat chloride test or by the presence of a CFTR gene mutation.

For newborns found through screening, clinical signs are not necessary.

1. **Immunoreactive trypsinogen (IRT) Test:**

A common newborn screening test called the Immunoreactive Trypsinogen (IPR) test looks for abnormally high levels of the blood protein known as IRT. A high IRT level might be an indication that someone has cystic fibrosis, but further research is needed to make the diagnosis.

2. Sweat Chloride Test:

The test that is most frequently used to identify cystic fibrosis is the sweat chloride test. It examines the perspiration for elevated salt concentrations. Utilizing a substance that, when activated by a small electric charge, causes the skin to sweat Sweat is gathered on a pad of paper or other surface and examined. If the perspiration is more salty than usual, cystic fibrosis is identified as the cause.

3. Sputum Test:

A sample of mucus is taken by the doctor during a sputum test. The sample can establish whether or not there is a lung infection. Additionally, it can identify the kind of bacteria that are present and the most effective drugs to treat them.

4. Blood Test:

A person with CF may get blood tests to assist assess their health. A little amount of blood is typically drawn using a syringe and submitted to a lab for analysis.

Nutritional status, vitamin levels, and other factors can be evaluated by blood tests. For diabetes, for hepatitis

1.5. Treatment for CF

There's no cure for cystic fibrosis, but medications and other therapies can ease symptoms. File naming and delivery

Medication:

You can be prescribed medications by your doctor to help your body absorb nutrients from meals, thin mucus, open your airways, and prevent infections. These comprise:



Fig: Treatment of CF

Antibiotics:

They improve the function of your lungs and can be used to prevent or cure lung infections. You can get them as tablets, an inhaler, or an injection.

Anti-inflammatory medicines:

These include ibuprofen and corticosteroids.

Bronchodilators:

These are delivered via inhaler. Your airways will be made more open and relaxed.

Mucus thinners:

They'll assist you in clearing the debris from your airways. They are delivered by an inhaler.

CFTR modulators:

These facilitate proper CFTR operation. They may improve the functionality of your lungs and aid in weight growth.

Combination therapy:

The novel drug elexacaftor/ivacaftor/tezacaftor (Trikafta) combines three CFTR modulators to effectively target and activate the CFTR protein.

Physical therapy for CF.:

This involves breathing techniques that force air through thick layers of mucus and against your chest wall. They facilitate clearing obstructed airways and make it simpler to cough up debris. Common exercises consist of:

• **Autogenously drainage** to do this, you exhale forcefully, or huff. This facilitates the passage of mucus by moving it from your smaller airways to the central airways.

• **An active breathing cycle.** This regulates breathing and eases the shoulders and upper chest, which can aid in clearing mucus and preventing airway obstructions. You take a deep breath, hold it, and puff for varying periods of time.

Surgical procedures:

- **Bowel surgery:** A portion of the bowel will be removed during this urgent operation. It could be carried out to clear a bowel obstruction.
- **Feeding tube:** Food nutrients may not be absorbed and digestion may be hampered by cystic fibrosis. It is possible to surgically put a feeding tube directly into the stomach or to insert one via the nose to provide sustenance.
- **Double-lung transplant:** This surgery can extend and enhance a cystic fibrosis patient's life when medical care alone is no longer sufficient to preserve lung health and physical performance.



Fig. 1 - (a) Cystic Fibrosis; (b) CFTR gene and protein

2. Literature Survey:

Cystic fibrosis patients' nasal epitheliums get CFTR gene transfer using liposomes:

Nine cystic fibrosis (CF) patients who received cationic liposomes combined with complementary DNA encoding the CF trans membrane conductance regulator (CFTR) and six CF patients who received liposomes alone were involved in a double-blind, placebo-controlled study, which was reported by Natasha J., et al. The response to reduced Cal in a few cases was typical for persons without CF. The majority of the treated people possessed transgene-produced plasmid DNA and RNA. Despite the encouraging findings, it is likely that longer expression times and better transfection efficiency would be needed to produce therapeutic effects. [2]

Diabetes associated with cystic fibrosis: Medical treatment:

Katie Larson et al. It has been established that increased pulmonary morbidity and mortality in cystic fibrosis patients are caused by the condition's connection to diabetes (CFRD). People with CF frequently require a rigorous insulin regimen, such as many daily injections of insulin pump therapy, hence insulin therapy is indicated as a type of treatment. However, lower doses than in type 1 diabetes mellitus. [3]

R. C. Boucher The aberrant ion transport characteristics of CF airway epithelia were assessed to a decreased airway surface liquid (ASL) volume, representing the combined deficiencies of rapid Na+ transport and the inability to produce Cl. Continued cumin synthesis results in "thickened" mucus plaques after PCL depletion, and mucus adheres to the surfaces of the airways as a result.[4]

Results from a Phase 2 Randomized Trial on the CFTR Potentiate Icenticaftor (QBW251) in COPD:

Steven M. and others assessed to evaluate the CFTR potentiator icenticaftor's effectiveness in treating COPD patients who have chronic bronchitis symptoms and airflow restriction.

In this double-blind, placebo-controlled study, individuals with COPD were randomized (2:1) to receive either icenticaftor 300 mg daily or a placebo. This non-confirmatory proof of concept study was powered for lung clearance index (LCI) and pre-bronchodilator FEV1 with an intended sample size of 90 participants.

Change from baseline in pre- and post-bronchodilator FEV1 on Day 29 was one of the main secondary goals. Change from baseline in LCI for icenticaftor versus placebo at Day 29 was the main result. Three significant exploratory results that were taken into consideration were sweat chloride, plasma fibrinogen, and sputum colonization. Cystic mucociliary clecoloniz, mucociliary icenicaftor, QBW251. [5]

The preclinical development of the invocator + tezacaftor treatment combination for cystic fibrosis:

The partial partial rescue of the misprocessing of F508del-CFTR with the potentiate invocator discovered by Lorenzo et al. through in vitro tests of the CFTR correctors (i.e. lumacaftor, tezacaftor) seems promise in providing an unparalleled clinical benefit in afflicted individuals.

Tezacaftor-ivacaftor therapy has been demonstrated to be less hazardous than lumacaftor-ivacaftor therapy despite having a similar clinical efficacy. Clinical effectiveness has enhanced as a result of triple therapy. [6]

The Invocator Experience: Change in Sweat Chloride as a Clinical End Point in Cystic Fibrosis Clinical Trials:

Anthony G., et al. presented evidence of a dose-response association between improvement in FEV1 and decrease in sweat chloride, a marker of CFTR function, in a clinical study to support invocator dose selection. If this relationship between FEV1 and sweat chloride were established, it would be considerably simpler to develop innovative drugs that target the defective CFTR. Invocator 150 mg bid significantly increased FEV1 (between 10% and 12%) and decreased sweat chloride (by roughly 50 moll/L) in phase 3 studies.

The fact that there is no connection between sweat chloride and FEV1 improvement draws attention to the wide range of physiological, environmental, and inherited factors that might potentially affect how severe a CF diagnosis is.[7]

Current treatment options for cystic fibrosis-related liver disease:

According to Katharina et AL analysis,'s cystic fibrosis-related liver disease (CFLD) has emerged as a major factor in the morbidity and death of people with the condition (CF). Ursodeoxycholic acid has been used for a long time, but its efficacy in CFLD is questionable, so it will be critical to assess the potential of CFTR modulators and targeted gene therapy in the near future.[8]

Increasing the effectiveness of inhaled medications for cystic fibrosis: Problems and new drug delivery techniques:

Ivana and others The capacity of the medication to cross regional extracellular and cellular barriers as well as its concentration and persistence at the lungs have both been shown to be significant drivers of the clinical outcomes of inhaled treatments. The focus of this study is on innovative delivery strategies for the local treatment of CF pulmonary disease. It begins with a brief explanation of the illness and the limitations on formulation imposed by CF lung barriers before discussing current and anticipated advancements in CF inhaled therapy.[9]

Inhaled Liposomal Antimicrobial Delivery in Lung Infections:

Matteo and co. assessed Clinical trials are being conducted on products, and antifungal and antibiotic formulations are now accessible for human use as a result of considerable liposome technological development. A liposome is a biocompatible, non-toxic vesicle that may enclose and transport an antibiotic, improving its therapeutic index.

It enhances compliance and lowers drug toxicity, which diminishes side effects on the respiratory system and improves tolerance. Ciprofloxacin, amphotericin B, tobramycin, and amikacin are some of the liposomal antibiotics used to treat lung infections.[10]

Targeting outer membrane proteins for Burkholderia vaccines: Thinking beyond the bug:

Burkholderia spp. are gram-negative, intrinsically resistant bacteria that cause nosocomial infections and environmental infections, as proven by Meganne et al. These pathogens mostly affect immunocompromised and cystic fibrosis patients, and they are spread from patient to patient or through contaminated objects and equipment.

There is presently no licensed vaccine against any Burkholderia pathogen. [11]

Intravenous versus oral antibiotics for eradication of Pseudomonasaeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial:

Pseudomonas aeruginosa infection in the lungs is one of the leading causes of death and morbidity in cystic fibrosis, according to Simon C. Langton et alevaluation. .'s If antibiotics are administered as soon as possible, infection can be treated. The goal of the trial was to compare oral ciprofloxacin to intravenous ceftazidime and tobramycin in terms of effectiveness and safety for treating P aeruginosa.

Between October 5, 2010, and January 27, 2017, 286 patients were randomly assigned to receive either intravenous or oral antibiotics. 55 (44%) of 125 participants in the intravenous group and 68 (52%) of 130 participants in the oral group were successful in achieving the primary outcome. Despite the fact that there was no statistically significant difference between the groups, individuals who were randomly assigned to the intravenous group were less

Interpretation:

In a greater proportion of cystic fibrosis patients, intravenous antibiotics were more expensive than oral therapy and did not entirely eliminate P aeruginosa. Although the intravenous group required fewer hospital stays than the oral group throughout the follow-up, intravenous eradication is not always more effective than oral treatment since it frequently requires hospitalisation. These results do not support the use of intravenous antibiotics to eradicate P aeruginosa in cystic fibrosis.[12]

Next-generation cystic fibrosis treatments: CFTR folding, function, and pharmacology:

Vertex Pharmaceuticals' development of TrikaftaTM (elexacaftor-tezacaftor-ivacaftor) is the outcome of in-depth investigation of the CFTR protein's structure, production in epithelial cells, and role as a ligand-gated anion. The Supplement, of which this article is a part, was financed by the European Cystic Fibrosis Society (ECFS). small molecule modulation and channels.

CFTR modulators are not available to all CF patients, and there is evidence that some CF patients taking them are experiencing disease progression, despite the substantial advancements.[13]

To better understand how CF mutations affect the assembly of CFTR, Cant S. et al. focused on revietechnolnt technical advancements. They also highlighted species-dependent variations in CFTR expression, stability, and function relevant to CF animal models and discovered combinations of two small molecule CFTR potentiators that restore function to rare CF mutations that have so far been insensitive to CFTR modulators. This evaluation was based on the 16th European Cystic Fibrosis Society Basic Science Conference, which took place in Dubrovnik, Croatia, from March 27 to 30, 2019.

The 16th European Cystic Fibrosis Society Basic Science Conference, held in Dubrovnik, Croatia, from March 27 to 30, 2019, served as the basis for this assessment.

CFTR folding, function, and pharmacology are complex concerns that each require separate investigation, although they are[14]

CFTR folding was demonstrated by Rodnina MV. Et al.: CFTR translational folding the very dynamic process of translational folding occurs when the developing polypeptide is gradually produced from N- to C-terminus in a complicated biological environment. The nearby ribosome has an impact on this process.[15]

Echo-Pagan B, et al. Evaluated Indirect analysis of the translation rate by ribosome profiling further confirmed ribosomal pausing within the region of synonymous codon alterations that were eliminated in the "Fast-CFTR" construct, showing that translation pace can influence how effectively the folding process works overall. These results led to the identification of synonymous single nucleotide polymorphisms (suns) known as "non-silent" synonymous mutations that have the ability to alter the structure of the CFTR. [16]

The role of Lipoid A4 in Cystic Fibrosis Lung Disease:

Anti-inflammatory therapy in Cystic Fibrosis:

Balfour-Lynn and colleagues assessed A recent systematic review of the risks and benefits of inhaled corticosteroids (ICS) in cystic fibrosis (CF), looking at data from 3 trials, came to the conclusion that there is not enough data to determine whether ICS are beneficial in CF, but that discontinuing use in those who are already taking it has been shown to be safe.[17]

Danforth, et al. It has been proven that using ICS might have a negative impact on growth. High-dose ibuprofen therapy was found to be associated with a significantly lower annual rate of decline in lung function (especially in children), according to a systematic review of the effectiveness of non-steroidal anti-inflammatory drugs in CF; however, ibuprofen use in therapy has not been widely accepted.le. [18]

The Specialized Pro-resolving Mediators:

Van Dyke TE and others acute inflammation is a defensive reaction that has been studied. It developed to kill off invaders while remaining self-contained and having an active resolution phase that is intended to reestablish tissue homeostasis. The non-immunosuppressive activities of SPM carry out the resolution phase. [19]

SerhanCN et al. and others It has been proven that prostaglandins are synthesized early, starting the inflammatory response. Following are leukotriene's, such as leukotriene B4 (LTB4), which has a role in the amplification and spread of Balfour-Ly... [20]

Anti-inflammatory properties of Lipoid A4:

Greer, TM, and others in a rat model of chronic airway inflammation and infection, evaluated LXA4 was shown to stop neutrophil inflammation and reduce infection. [21]

DW Hay and others demonstrated the ALX/FPR2 receptor is the mechanism via which LXA4's pro-resolution qualities work. The ALX/FPR2 is a G protein-coupled receptor that is primarily produced by mammalian phagocytic leukocytes. It has seven Tran's membrane domains. Since other pro-resolution mediators, such resolving D, also work through this receptor, LXA4 is not the only pro-resolution mediator known to defense host defense and inflammation...
[22]

Monitoring of blood sugar continuously in cystic fibrosis a helpful primer: Diagnostic work:

L. Plush and others evaluated because the early detection and treatment of the disorder are now priorities since the disease typically presents without the polyuria and polydipsia typical of diabetes. Clinical deterioration has also been connected to the pre-diabetic state. [23]

Studies have discovered that both abnormalities in CGM and insulin secretion are common in CF, even at a young age and despite normal glucose tolerance on oral glucose tolerance testing. Waters SA, et al. demonstrated CGM detects early glucose abnormalities before traditional diabetes screening tests.[24]

Lumacaftor and Ivacaftor administered by nanostructured lipid carriers in the treatment of cystic fibrosis:

Method:

Protein expression :

W.M. Weber and others Demonstrated Protein Extraction: 16HBE14o- and CFBE41o- cells were cultivated in fibronectin-coated flasks until confluent. Cells were trypsin zed, centrifuged at 500 g for 5 min, and then lysed in 55 l of lists buffer (TRIS1 mm, Nalco 15 mm, EDTA 0.2 mm, 2% Triton X-100), followed by[25]

Jiang and others evaluated after that, to eliminate non-soluble elements, the contents were centrifuged for 5 min (14,000 g) at 4 °C. The pellet was then discarded, and the supernatant was transferred to additional tubes. The Bradford technique was used to measure the protein concentration.[26]

3. T. Minco et al. looked at the therapy for inhalation exposure. In order to aerosolize the particles, a one-jet Collision nebulizer (BGI Inc., Waltham, MA) was utilized with dry, filtered air (Airgas East, Salem, NH) at an aerosolization flow rate of 2 L/min. An additional airflow of 2-3 L/min was then added to dilute and desiccate the resultant aerosol.

Conclusions: Combining lu-macaftor and invocator—two drugs with different mechanisms of action—proved to be extremely effective in treating the pulmonary symptoms of cystic fibrosis when breathed into the lungs. Studies conducted in animals confirmed the basic idea and showed the outstanding therapeutic potential of simultaneous and combinatorial local lung delivery of both drugs using lipid nanoparticles... [27]

4. Conclusion:

Based on a review of recent research, we were able to determine if CF is among the most prevalent genetic diseases among North American races. One in every three, 200 live white babies is affected by CF. Sometimes, CF in Indian children is discovered at an advanced stage.

Different people experience CF symptoms differently and to varying degrees. The symptoms of various different health conditions are similar to those of CF. this could make CF difficult to detect or diagnose. A mutation in the fibrosis transmembrane electrical phenomenon regulator (CFTR) sequence is the primary genetic basis for CF.

The incorrect CF sequence must be present in both parents for the illness to be passed on to the child. There is one in every older person's carry-to sequence.

REFERENCES

1) Gaskin K, et al: Pancreatic fluid secretion and protein hyper concentration in cystic fibrosis. N Engle J Med 1985; 312: 329–334.
2) Natasha J., et al. "Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis." *Nature medicine* 1.1 (1995): 39-46.
3) Katie Larson et al. “Cystic fibrosis related diabetes: Medical management.” *Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society* vol. 18 Supple 2 (2019): S10-S18.
4) Boucher, R. C. "New concepts of the pathogenesis of cystic fibrosis lung disease." *European Respiratory Journal* 23.1 (2004): 146-158.
5) Steven M et al. “Efficacy and Safety of the CFTR Potentiate Icenticaftor (QBW251) in COPD: Results from a Phase 2 RandomizedTrial.” *International journal of chronic obstructive pulmonary disease* vol. 15 2399-2409.
6) Lorenzo et al. “The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis.” *Expert opinion on drug discovery* vol. 15,8 (2020): 873-891.
7) Anthony G., et al. "Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the invocator experience." *Chest* 143.1 (2013): 14-18.
8) Katharina et al. "Current treatment options for cystic fibrosis-related liver disease." *International journal of molecular sciences* 21.22 (2020): 8586.
9) Ivana, et al. "Improving the efficacy of inhaled drugs in cystic fibrosis: challenges and emerging drug delivery strategies." *Advanced drug delivery reviews* 75 (2014): 92-111.

10) Matteo et al. "Inhaled Liposomal Antimicrobial Delivery in Lung Infections." *Drugs* vol. 80, 13 (2020): 1309-1318.

11) Megan E et al. "Thinking Outside the Bug: Targeting Outer Membrane Proteins for *Burkholderia* Vaccines." *Cells* vol. 10, 3 Feb. 2021, 495. 25

12) Simon C Langton et al. "Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial." *The Lancet. Respiratory medicine* vol. 8,10 (2020): 975-986.

13) Hafkemeyer S, et al. CFTR: new insights into structure and function and implications for modulation by small molecules. J Cyst Fibrous 2019 Nov 21.

14) Canto S. et al. From the endoplasmic reticulum to the plasma membrane: mechanisms of CFTR folding and trafficking. Cell Moll Life Sic 2017; 74:39–55.

15) Ronin MV. Et.al Translational protein folding on the ribosome monitored in real time. Science 2015; 350:1104–7.

16) Echo-Pagan B, et al. Codon bias and the folding dynamics of the cystic fibrosis Tran's membrane conductance regulator. Cell Moll Boil Let 2016; 21:23.

17) Balfour-Lynn 1M, Welch K Inhale corticosteroids for cystic cfibrosis.Cochrane Database Syst Rev 11: CDOet al.O1915. (2012)11

18) Davfibro.et al. Non! To non-steroidalanti-inflammatory therapy for inflammatory lung disease in cystic fibrosis (at least at the moment).J Pediatric (2007) 151:228-230.

19) Van Dyke TE et al. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators.NatRevImmunol8: (2008) 349-361.15.

20) Saran CN et al. Lipid mediator class switching during acute inflammation :signals in resolution.NatImmunol2: (2001) 612-619.16

21) Greer TM, et al. Defective lipoid-mediated anti-inflammatory activity in the cystic fibrosis airway.NatImmunol5: (2004) 388- 392.

22) Hay Wet al. International union of Pharmacology XXXVII .Nomenclature for leukotriene and lipoid receptors .Pharmacology Rev 55: (2003) 195-227.

23) Plush L, et al. Peak OGTT glucose is associated with lower lung function in young children with cystic fibrosis. Cyst Fibrous May 21 2019.

24) Waters SA, et al .Early glucose abnormalities are associated with pulmonary inflammation in young children with cystic fibrosis. J Cyst Fibrous Apr 26 2019.

25) W.M. Weber, et al. Cystic fibrosis trans membrane con-distance regulator-mRNA delivery: a novel alternative for cystic fibrosis gene therapy, J.Gene Med. 15 (2013) 414–426

26) . Jiang, et al. Preliminary study on total protein extraction methods from Enterococcus facials biofilm, Genet. Mol. Res. 15 (2016).

27) T. Minco, et al. Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice, J. Aerosol. Med. Palm. DrugDeliv. 26 (2013) 345–354.